Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EvolveImmune United
Branford, Connecticut, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical data demonstrates robust single-agent anti-tumor activity for EVOLVE-104 in patient-derived tumor models of bladder and lung cancer, with promising activity in combination with anti-PD1 therapy
- Therapeutic areas
- OncologyImmunology
- Modalities
- Trispecific T cell engagerRecombinant proteinBispecific monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Partnerships
AbbVie (collaboration and option-to-license agreement for next-generation cancer biotherapeutics)University of Oxford Kennedy Institute of Rheumatology (research collaboration)
Beyond the preview
Go deeper on EvolveImmune United.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EvolveImmune United.